)
Visual
test
Laboratorios Farmaceuticos Rovi
Laboratorios Farmaceuticos Rovi (ROVI) investor relations material
Laboratorios Farmaceuticos Rovi Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary6 Nov, 2025
Executive summary
Operating revenue for the first nine months of 2025 was €525.1 million, down 7% year-over-year, mainly due to a 28% decline in CDMO business, while specialty pharma sales rose 10% to €343.4 million.
Okedi® sales surged 102% to €41.0 million, and the heparin franchise grew 7% to €189.8 million, with enoxaparin sales up 11% to €112.8 million.
Gross margin improved to 67.1% (up 3.5 pp), aided by R&D grants, higher-margin product sales, and lower LMWH raw material prices.
EBITDA fell 11% to €149.5 million, and net profit declined 14% to €97.7 million, reflecting lower revenues and increased R&D expenses.
Strategic milestones included agreements with Roche, Sandoz, and BMS, acquisition of a Phoenix facility, and a €36.3 million R&D grant for the LAISOLID project.
Financial highlights
Specialty pharma business offset CDMO weakness, with Okedi®, Neparvis®, and contrast agents as key growth drivers.
CDMO sales dropped 28% to €181.7 million due to lower Moderna-related revenues and a temporary plant closure for upgrades.
SG&A expenses rose 2% to €177.9 million, and R&D expenses increased 42% to €24.7 million, reflecting clinical trial activity.
Free cash flow more than doubled to €63.3 million, and gross cash position rose to €51.2 million.
Capex increased 14% to €38.5 million, mainly for plant expansions, new filling lines, and ISM® industrialization.
Outlook and guidance
2025 operating revenue expected to decrease by a mid-single-digit percentage versus 2024.
2026 operating revenue projected to grow by a high single-digit to low double-digit percentage, with growth levers including new product launches, CDMO agreements, and AI-powered diagnostics.
Full-year 2025 enoxaparin biosimilar sales expected to rise mid-single-digit; bemiparin sales to increase low single-digit.
CDMO growth drivers beyond 2025
R&D spend impact on ISM® pipeline value
Sustainability of gross margin expansion
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- PNDORA
2025 organic growth reached 6%, with EBIT margin at 23.9% and cautious 2026 outlook. - PRU
Earnings rose 12% to $6.6B; Japan sales pause to cut 2026 earnings by $300M-$350M. - FTV
2025 results beat guidance, with strong EPS growth and $1.6B in share repurchases. - BEN
All proposals passed, with strong financial growth and strategic progress in alternatives and ETFs. - APAM
AUM hit $180B in 2025, with strong credit/alternatives growth and higher dividends. - OXBR
Tokenized reinsurance contracts on Solana open Florida’s high-return market to global investors. - KMT
Q2 sales and earnings surged, driving raised full-year guidance and strong segment growth. - RNR
Net income hit $2.65B in 2025, with 30.8% book value growth despite major loss events. - WNC
Q4 2025 revenue was $321.5M with losses, but Parts & Services grew 32.6% year-over-year. - AGI
Path to 1M oz gold by 2029, with lower costs, strong cash flow, and major expansions advancing.
Next Laboratorios Farmaceuticos Rovi earnings date
Q4 202525 Feb, 2026
Laboratorios Farmaceuticos Rovi
Next Laboratorios Farmaceuticos Rovi earnings date
Q4 202525 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Laboratorios Farmacéuticos Rovi S.A. is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of proprietary and in-licensed drugs. It serves therapeutic areas including cardiovascular, hematology, and endocrinology. The company is headquartered in Madrid, Spain, and its shares are listed on the BME.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage